Albireo Pharma, Inc. (ALBO) Major Shareholder Phase4 Partners Ltd Sells 100,000 Shares of Stock

Albireo Pharma, Inc. (NASDAQ:ALBO) major shareholder Phase4 Partners Ltd sold 100,000 shares of the business’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $34.44, for a total transaction of $3,444,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Shares of Albireo Pharma, Inc. (NASDAQ ALBO) opened at $34.77 on Friday. The firm has a market cap of $379.85, a P/E ratio of 16.02 and a beta of 1.43. Albireo Pharma, Inc. has a one year low of $15.31 and a one year high of $39.87.

Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.12. research analysts predict that Albireo Pharma, Inc. will post -3.42 EPS for the current year.

A number of research analysts have issued reports on ALBO shares. Zacks Investment Research raised shares of Albireo Pharma from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research note on Tuesday, January 16th. Wedbush reissued a “buy” rating on shares of Albireo Pharma in a research note on Wednesday, January 3rd. BidaskClub raised shares of Albireo Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday. Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a research note on Friday, November 17th. Finally, Roth Capital initiated coverage on shares of Albireo Pharma in a research note on Wednesday, November 15th. They issued a “buy” rating and a $92.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $54.50.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at

About Albireo Pharma

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with's FREE daily email newsletter.

Leave a Reply